Comparative Pharmacology
Head-to-head clinical analysis: NIMBEX PRESERVATIVE FREE versus PAVULON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NIMBEX PRESERVATIVE FREE versus PAVULON.
NIMBEX PRESERVATIVE FREE vs PAVULON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, blocking acetylcholine binding and inhibiting neuromuscular transmission, resulting in skeletal muscle paralysis.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, blocking transmission of nerve impulses to skeletal muscle.
0.15-0.2 mg/kg IV bolus for intubation; maintenance: 1.5-2 mcg/kg/min IV infusion
0.04-0.1 mg/kg IV bolus for intubation; maintenance: 0.01-0.015 mg/kg IV every 25-60 minutes as needed or continuous IV infusion: 1-2 mcg/kg/min.
None Documented
None Documented
Terminal elimination half-life is approximately 20-30 minutes (mean 24 minutes) in patients with normal renal and hepatic function; clinically, this short half-life supports rapid recovery after discontinuation and suitability for continuous infusion.
Terminal elimination half-life 100-120 minutes in adults with normal renal function; prolonged in renal impairment.
Primarily via Hofmann elimination (approximately 80%) and ester hydrolysis by nonspecific plasma esterases; renal excretion of unchanged drug accounts for less than 5% of the dose, and biliary/fecal elimination is minimal (less than 1%).
Renal 80-100% as unchanged drug and metabolites; biliary/fecal negligible (<5%).
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent